News
Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo ...
Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...
The companies, which have at times had an adversarial relationship, also said they would develop a roadmap to continue their ...
Hims & Hers stock surges after Novo Nordisk announces Wegovy will be offered through telehealth platforms as shortages ease ...
The $599 price is also vastly lower than the other GLP-1s offered on Hims & Hers: it provides Ozempic for $1,799 a month, Mounjaro for $1,899 a month and Zepbound for $1,899 a month. This is a ...
In essence, Hims & Hers is embracing a "if you can't beat 'em, join 'em" approach that gives their customers more options.
Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.
Novo Nordisk A/S is partnering with telehealth companies including Hims & Hers Health Inc., LifeMD Inc., and Ro to offer ...
Hims & Hers said it would add branded tirzepatide, the active ingredient for Mounjaro and Zepbound, to its platform. Eli Lilly said on the same day that it "has no affiliation" with Hims & Hers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results